DOSING IN PATIENTS WITH cUTI1
4 grams* administered every 8 hours by intravenous (IV) infusion over 3 hours in patients ≥18 years of age with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73 m2
The duration of treatment can be up to 14 days
4 g of VABOMERE=2 g meropenem and 2 g of vaborbactam.
Dosage adjustment is recommended in patients with renal impairment who have an eGFR <50 mL/min/1.73 m2.
aAs calculated using the Modification of Diet in Renal Disease (MDRD) formula as follows: eGFR (mL/min/1.73m2) =175 x (serum creatinine)-1.154 x (age)-0.203 x (0.742 if female) x (1.212 if African American).
bAll doses of VABOMERE are administered IV over 3 hours.
cDoses adjusted for renal impairment should be administered after a hemodialysis session.
dThe total duration of treatment is for up to 14 days.
VABOMERE is supplied as a dry powder in a single-dose vial that must be constituted and further diluted using aseptic technique prior to intravenous infusion as outlined below. VABOMERE does not contain preservatives.
Visually inspect the diluted VABOMERE solution for particulate matter and discoloration (the color of the VABOMERE infusion solution for administration ranges from colorless to light yellow). Discard unused portion after use.
Reference: 1. VABOMERE [package insert]: Melinta Therapeutics, Inc.
VABOMERE® (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
VABOMERE is contraindicated in patients with known hypersensitivity to any components of VABOMERE (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.
The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea.Please see full Prescribing Information.